Cue Biopharma Reports Two Objective Responses (1 cPR and 1uPR) in First Interim Update from Dose Escalation Portion of Ongoing Phase 1 Combination Study of CUE-101 and KEYTRUDA® in First Line Patients with HPV+ Recurrent/Metastatic Head and Neck CancerGlobeNewsWire • 01/26/22
Cue Biopharma to Host Business Update Call and Webcast for Ongoing CUE-101 Clinical TrialsGlobeNewsWire • 01/20/22
Cue Biopharma Announces Appointment of Patricia Nasshorn as Chief Business OfficerGlobeNewsWire • 12/15/21
Cue Biopharma to Present at the Piper Sandler 33rd Annual Healthcare ConferenceGlobeNewsWire • 11/22/21
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in NovemberGlobeNewsWire • 11/10/21
Analysts Estimate Cue Biopharma, Inc. (CUE) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 11/09/21
Cue Biopharma Announces Publication in The Journal of Clinical Investigation Highlighting Immuno-STAT Biologics for the Treatment of Chronic Infectious DiseasesGlobeNewsWire • 10/21/21
Cue Biopharma Announces Publication in Nature Journal, Scientific Reports, of Immunotherapeutic Platforms Immuno-STAT and Neo-STATGlobeNewsWire • 09/28/21
Cue Biopharma Granted U.S. Patents on Lead Clinical Program Novel Drug Product Candidate CUE-101GlobeNewsWire • 09/21/21
Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/18/21
Cue Biopharma Reports Second Quarter 2021 Results, Recent Data Updates of CUE-101 Phase 1 Dose Escalation and Expansion Study, Platform Progress and Business HighlightsGlobeNewsWire • 08/17/21
Cue Biopharma to Present Corporate Update at the Upcoming BTIG Virtual Biotechnology ConferenceGlobeNewsWire • 08/03/21
Earnings Preview: Cue Biopharma, Inc. (CUE) Q2 Earnings Expected to DeclineZacks Investment Research • 07/30/21
Cue Biopharma Announces First Patient Dosed in Part B Patient Expansion of CUE-101 Phase 1 Monotherapy Trial in HPV+ Second Line and Beyond HNSCCGlobeNewsWire • 06/10/21
Cue Biopharma to Present at the 2021 Federation of Clinical Immunology Societies (FOCIS) Virtual Annual MeetingGlobeNewsWire • 06/03/21
Cue Biopharma, Inc. (CUE) CEO Daniel Passeri on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/18/21
Cue Biopharma Reports First Quarter 2021 Results, Recent Updates of CUE-101 Phase 1 Dose Escalation Study, Platform Progress and Business HighlightsGlobeNewsWire • 05/17/21
Strength Seen in Cue Biopharma, Inc. (CUE): Can Its 27.7% Jump Turn into More Strength?Zacks Investment Research • 05/11/21
Cue Biopharma's Stock Shoots Up After CUE-101 Shows Promise In Early-Stage Head & Neck Cancer StudyBenzinga • 05/10/21
Cue Biopharma Reports Confirmed Partial Response (PR) in Ongoing Phase 1 Monotherapy Study of CUE-101 in Late Stage Second Line and Beyond Patients with HPV+ Recurrent/Metastatic Head and Neck CancerGlobeNewsWire • 05/10/21
Cue Biopharma, Inc. (CUE) CEO Daniel Passeri on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/17/21
Cue Biopharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business HighlightsGlobeNewsWire • 03/16/21
Cue Biopharma to Present Corporate Overview and Clinical Progress at the Upcoming Oppenheimer 31st Annual Healthcare ConferenceGlobeNewsWire • 03/15/21